Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thomas E.J. Chavas"'
Autor:
Brian Lee, Thomas E.J. Chavas, Guilhem F. Rerolle, Fang-Yi Su, Debashish Roy, Elaine Limqueco, Selvi Srinivasan, T. Eoin West, Lara Lovelace-Macon, Patrick S. Stayton, Shawn J. Skerrett, Daniel M. Ratner
Publikováno v:
J Control Release
Pulmonary melioidosis is a bacterial disease with high morbidity and a mortality rate that can be as high as 40% in resource-poor regions of South Asia. This disease burden is linked to the pathogen's intrinsic antibiotic-resistance and protected int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee847b7e3198ca8e0422d52e40fbe20
https://pubmed.ncbi.nlm.nih.gov/33221351
https://pubmed.ncbi.nlm.nih.gov/33221351
Autor:
Hans E. Huber, Jing Zhang, Rosemary Rochford, Paul A. Burke, Duy-Khiet Ho, Brandon S. Pybus, Debashish Roy, Ayumi Pottenger, Siobhan M. Flaherty, Pamela Strauch, Vladimir A. Vlaskin, Patrick S. Stayton, Conner L. Jackson, Thomas E.J. Chavas, Mahdi Maktabi, Hsiuling Lin, Clare L.M. LeGuyader, Selvi Srinivasan, David Wesche, Qigui Li
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 331
Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium vivax. A single oral dose of tafenoquine leads to high e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6678b8ca58b45191d6bfcca05c991316
https://pubmed.ncbi.nlm.nih.gov/33378692
https://pubmed.ncbi.nlm.nih.gov/33378692
Autor:
Clare L.M. LeGuyader, Selvi Srinivasan, Debashish Roy, Almar Postma, John Chiefari, Vladimir A. Vlaskin, Jessica M. Snyder, Patrick S. Stayton, Duy-Khiet Ho, Thomas E.J. Chavas, Ciana L. Lopez
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 329
Clinical studies have validated that antiretroviral (ARV) drugs can serve as an HIV pre-exposure prophylactic (PrEP) strategy. Dosing adherence remains a crucial factor determining the final efficacy outcomes, and both long-acting implants and inject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20dcb6b42b127449eed9f746f90e0626
https://pubmed.ncbi.nlm.nih.gov/33217474
https://pubmed.ncbi.nlm.nih.gov/33217474